Ascletis first to file biotech IPO under new HK regimeAscletis Pharma has emerged as the first biotechnology firm to test the waters of Hong Kong’s new listing regime, after filing a draft prospectus on Monday.

Ascletis Pharma has emerged as the first biotechnology firm to test the waters of Hong Kong’s new listing regime, after filing a draft prospectus on Monday.http://www.globalcapital.com/article/b183d3cf2lf2w1/ascletis-first-to-file-biotech-ipo-under-new-hk-regime[Collection]